. 2018 Oct 14;194(3):391–399. doi: 10.1111/cei.13206

Table 2.

Patient characteristics (n = 231) at month 36

Larsen score (mean ± s.d.)^a	4·2 ± 4·4
Larsen progress (mean ± s.d.)^a	1·8 ± 2·8
Oral corticosteroids, n (%)	109 (47·2)
csDMARD single therapy, n (%)	138 (59·7)
csDMARD combination therapy, n (%)	42 (18·2)
bDMARD, n (%)	28 (12·1)

csDMARD = conventional synthetic disease‐modifying anti‐rheumatic drug (single therapy including methotrexate (MTX), salazopyrin (SSZ), antimalaria or leflunomide. combination therapy including different combinations of MTX, SSZ, anti‐malarial and imurel) and bDMARD = biological disease‐modifying anti‐rheumatic drug. ^a Data available from 155 patients; s.d. = standard deviation.